10x Genomics said preliminary Q4 revenue of $166 million — ahead of consensus — with consumables revenue rising about 6% to approximately $141.7 million while instrument revenue declined sharply (single‑cell instruments down 44%). For full‑year 2025, the company anticipates roughly $642.8 million in revenue (or $598.7 million excluding patent‑settlement items) and projected ongoing strength in consumables and services despite a pullback in instrument placements.